We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MDNA (MC C$36 M) Cash (C$20 M) Approval on P2 Data
An SI Board Since September 2017
Posts SubjectMarks Bans Symbol
2 1 0 MDNA
Emcee:  BioHero Type:  Moderated
Here is a very attractive and brutally undervalued canadian company called Medicenna (MDNA.TO) which is listed since March thats why its also undicovered . This Cancer Play has a Phase 2 trial in recurrent Glioblastoma ongoing a $650 Million Market , they expect to complete enrollment by year end and to report results in early Q1 2018 . If the results are positive then they can file for accelerated approval in 2H 2018 and this makes this company with a terrible low valuation of only C$ 36 Million a super attractive opportunity which has 10 bagger potential easily on positive phase 2 results in Q1 2018 and FDA approval .Please do your own DD and realize the mega potential .GL

Medicenna Therapeutics (MDNA.TO)

Market Cap C$36 Million
Cash : C$ 20 Million << enough untill Q1 2019
Price : $1.50

Shares Out: 24.3 Million ( 15.5 Million shares held by Insider alone )

Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval

New Presentation

Fact Sheet

Insider Ownership :

Aries Biologics, Inc. 5 500 000
Rosemina Merchant 5 050 000
Fahar Merchant 5 050 000
Elizabeth Williams 5 300
Chandrakant J. Panchal, PhD 1 000
Trevor P. Wong-Chor 714

 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):